- Home
- YI vs SERA Comparison
YI vs SERA Comparison
Compare YI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- SERA
- Stock Information
- Founded
- YI 2010
- SERA 2008
- Country
- YI China
- SERA United States
- Employees
- YI N/A
- SERA N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- SERA Precision Instruments
- Sector
- YI Consumer Staples
- SERA Health Care
- Exchange
- YI Nasdaq
- SERA Nasdaq
- Market Cap
- YI 70.0M
- SERA 60.3M
- IPO Year
- YI N/A
- SERA 2021
- Fundamental
- Price
- YI $8.00
- SERA $1.92
- Analyst Decision
- YI
- SERA
- Analyst Count
- YI 0
- SERA 0
- Target Price
- YI N/A
- SERA N/A
- AVG Volume (30 Days)
- YI 11.5K
- SERA 380.9K
- Earning Date
- YI 06-19-2025
- SERA 08-06-2025
- Dividend Yield
- YI N/A
- SERA N/A
- EPS Growth
- YI N/A
- SERA N/A
- EPS
- YI N/A
- SERA N/A
- Revenue
- YI $1,984,717,013.00
- SERA $115,000.00
- Revenue This Year
- YI N/A
- SERA $390.13
- Revenue Next Year
- YI N/A
- SERA $440.54
- P/E Ratio
- YI N/A
- SERA N/A
- Revenue Growth
- YI N/A
- SERA N/A
- 52 Week Low
- YI $4.15
- SERA $1.37
- 52 Week High
- YI $12.90
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- YI 49.11
- SERA 49.30
- Support Level
- YI $7.40
- SERA $1.37
- Resistance Level
- YI $8.69
- SERA $1.94
- Average True Range (ATR)
- YI 0.41
- SERA 0.21
- MACD
- YI -0.02
- SERA 0.09
- Stochastic Oscillator
- YI 46.51
- SERA 87.30
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.